Copy to clipboard 
Zimmer Biomet reported 1Q22 orthopedic sales of $1.66 billion, +3.9% vs. 1Q21.
In the company’s first quarter since spinning off its spine and dental businesses, Zimmer Biomet benefitted from a faster than expected elective procedure recovery as COVID relents in parts of the world. The rebound of elective procedures more than offset other pressures, like staffing shortages and inflation.
The company’s ZBEdge digital portfolio bolstered both knee and hip replacement sales. The company has over 600 ROSA robotic units in the field currently. Zimmer Biomet leadership said they saw no indications of hospital spending constraints to this point. However, the company is strategically prioritizing share-agreement placements over outright sales.
Zimmer Biomet’s trauma segment came under pressure in the first quarter, largely due to China’s COVID surge and volume-based purchasing policy. However, VBP will be a net neutral for the company in 2022.
All told, the strong start to 2022 spurred Zimmer Biomet to raise and tighten its guidance range. The company now expects full-year reported growth between -1.5% to +0.5% compared to 2021.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
| 1Q22 | 1Q21 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $1,247.8 | $1,188.4 | $59.4 | 5% |
| Knees | $676.1 | $626.6 | $49.5 | 7.9% |
| Hips | $453.0 | $447.0 | $6.0 | 1.3% |
| Extremities | $118.8 | $114.8 | $3.9 | 3.4% |
| Trauma | $155.3 | $158.7 | ($3.4) | (2.2%) |
| Sports Medicine | $47.9 | $43.8 | $4.1 | 9.3% |
| Orthobiologics | $57.5 | $56.4 | $1.1 | 2% |
| Other | $154.7 | $154.1 | $0.6 | 0.4% |
| Total | $1,663.2 | $1,601.4 | $61.8 | 3.9% |
Orthopedic Sales by Geography
| 1Q22 | 1Q21 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $941.2 | $889.2 | $52.0 | 5.8% |
| OUS | $722.0 | $712.2 | $9.8 | 1.4% |
| EMEA | $371.8 | $356.1 | $15.7 | 4.4% |
| Asia Pacific | $303.2 | $313.4 | ($10.1) | (3.2%) |
| Resto World | $46.9 | $42.7 | $4.2 | 9.8% |
| Total | $1,663.2 | $1,601.4 | $61.8 | 3.9% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $1,663.2 | |
| Cost of Sales | $500.0 | 30.1% |
| Selling and Admin | $684.5 | 41.2% |
| R & D | $96.9 | 5.8% |
| Other | $367.6 | 22.1% |
| Net Earnings | $14.2 | 0.9% |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Zimmer Biomet reported 1Q22 orthopedic sales of $1.66 billion, +3.9% vs. 1Q21.
In the company's first quarter since spinning off its spine and dental businesses, Zimmer Biomet benefitted from a faster than expected elective procedure recovery as COVID relents in parts of the world. The rebound of elective procedures more than offset other...
Zimmer Biomet reported 1Q22 orthopedic sales of $1.66 billion, +3.9% vs. 1Q21.
In the company’s first quarter since spinning off its spine and dental businesses, Zimmer Biomet benefitted from a faster than expected elective procedure recovery as COVID relents in parts of the world. The rebound of elective procedures more than offset other pressures, like staffing shortages and inflation.
The company’s ZBEdge digital portfolio bolstered both knee and hip replacement sales. The company has over 600 ROSA robotic units in the field currently. Zimmer Biomet leadership said they saw no indications of hospital spending constraints to this point. However, the company is strategically prioritizing share-agreement placements over outright sales.
Zimmer Biomet’s trauma segment came under pressure in the first quarter, largely due to China’s COVID surge and volume-based purchasing policy. However, VBP will be a net neutral for the company in 2022.
All told, the strong start to 2022 spurred Zimmer Biomet to raise and tighten its guidance range. The company now expects full-year reported growth between -1.5% to +0.5% compared to 2021.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
| 1Q22 | 1Q21 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $1,247.8 | $1,188.4 | $59.4 | 5% |
| Knees | $676.1 | $626.6 | $49.5 | 7.9% |
| Hips | $453.0 | $447.0 | $6.0 | 1.3% |
| Extremities | $118.8 | $114.8 | $3.9 | 3.4% |
| Trauma | $155.3 | $158.7 | ($3.4) | (2.2%) |
| Sports Medicine | $47.9 | $43.8 | $4.1 | 9.3% |
| Orthobiologics | $57.5 | $56.4 | $1.1 | 2% |
| Other | $154.7 | $154.1 | $0.6 | 0.4% |
| Total | $1,663.2 | $1,601.4 | $61.8 | 3.9% |
Orthopedic Sales by Geography
| 1Q22 | 1Q21 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $941.2 | $889.2 | $52.0 | 5.8% |
| OUS | $722.0 | $712.2 | $9.8 | 1.4% |
| EMEA | $371.8 | $356.1 | $15.7 | 4.4% |
| Asia Pacific | $303.2 | $313.4 | ($10.1) | (3.2%) |
| Resto World | $46.9 | $42.7 | $4.2 | 9.8% |
| Total | $1,663.2 | $1,601.4 | $61.8 | 3.9% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $1,663.2 | |
| Cost of Sales | $500.0 | 30.1% |
| Selling and Admin | $684.5 | 41.2% |
| R & D | $96.9 | 5.8% |
| Other | $367.6 | 22.1% |
| Net Earnings | $14.2 | 0.9% |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
